Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C-H Kao

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Asia-Pacific Journal of Clinical Oncology|September 3, 2011
Second-line therapy for castrate-resistant prostate cancer: a literature reviewS C-H Kao, E Hovey, G Marx
British Journal of Cancer|April 10, 2014
Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'S C-H Kao, N van Zandwijk, S Clarke
Current Drug Targets|October 21, 2009
Predictive markers for haematological toxicity of pemetrexedS C H Kao, V H Phan, S J Clarke
Internal Medicine Journal|August 23, 2012
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, AustraliaS C-H Kao, S Clarke, J Vardy, et al.
Internal Medicine Journal|March 20, 2010
Malignant mesotheliomaS C-H Kao, G Reid, K Lee, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Asia-Pacific Journal of Clinical Oncology|September 3, 2011
Second-line therapy for castrate-resistant prostate cancer: a literature reviewS C-H Kao, E Hovey, G Marx
British Journal of Cancer|April 10, 2014
Comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'S C-H Kao, N van Zandwijk, S Clarke
Current Drug Targets|October 21, 2009
Predictive markers for haematological toxicity of pemetrexedS C H Kao, V H Phan, S J Clarke
Internal Medicine Journal|August 23, 2012
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, AustraliaS C-H Kao, S Clarke, J Vardy, et al.
Internal Medicine Journal|March 20, 2010
Malignant mesotheliomaS C-H Kao, G Reid, K Lee, et al.
Pageof 1